Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | BCR | P11274 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18338504 | 0.71 | LRRK2 (0.39) | — | |
| SCHEMBL23099048 | 0.68 | CREBBP (0.46) | ALDH1A1 | |
| SCHEMBL23087784 | 0.67 | PRMT5 (0.39) | — | |
| SCHEMBL23087160 | 0.67 | PRMT5 (0.40) | ALDH1A1 | |
| SCHEMBL20596105 | 0.66 | CREBBP (0.34) | — | |
| SCHEMBL24121007 | 0.64 | POLB (0.35) | — | |
| SCHEMBL23087887 | 0.64 | PRMT5 (0.39) | — | |
| SCHEMBL23087794 | 0.63 | PRMT5 (0.43) | ALDH1A1LMNA | |
| SCHEMBL23087328 | 0.62 | PRMT5 (0.42) | ALDH1A1LMNA | |
| SCHEMBL23087154 | 0.61 | ALDH1A1 (0.46) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042901-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2025-02-06 | — | — | US | disclosed |
| US-12139484-B2 | Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| CN-110023290-B | Heteroaryl carboxamide compounds as RIPK2 inhibitors | 勃林格殷格翰国际有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220081437-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2022-03-17 | — | — | US | disclosed |
| US-11130754-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-28 | — | — | US | disclosed |
| US-11130754-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-28 | — | — | US | disclosed |
| EP-3512833-B1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3512833-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | Boehringer Ingelheim International GmbH (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-20190048000-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2019-02-14 | — | — | US | disclosed |
| US-20190048000-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2019-02-14 | — | — | US | disclosed |
| US-10138241-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| WO-2018052772-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018052772-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-22 | — | — | WO | disclosed |
| US-20180072717-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072717-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072717-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048000-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | RIPK2 1/4885ABL1 1019/4885BCR 3680/4885 |
| US-20180072717-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK3 | RIPK2 1/4885ABL1 928/4885BCR 3452/4885 |
| US-10138241-B2 | Substituted benzamides as RIPK2 inhibitors | RIPK2, RIPK4, RIPK1 | RIPK2 1/4885ABL1 590/4885BCR 1230/4885 |
| US-20220081437-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK3 | RIPK2 1/4885ABL1 928/4885BCR 3452/4885 |
| US-11130754-B2 | Substituted benzamides as RIPK2 inhibitors | RIPK2, RIPK4, RIPK1 | RIPK2 1/4885ABL1 590/4885BCR 1230/4885 |
| US-20250042901-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | RIPK2 1/4885ABL1 1019/4885BCR 3680/4885 |
| US-12139484-B2 | Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease | RIPK2, RIPK4, RIPK1 | RIPK2 1/4885ABL1 1430/4885BCR 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.